Preparing for success in modernizing the science behind the development and regulation of medical products
ACDRS 2023 Session 1 - The Medical Product Development Enterprise: Past, Present, and Future Perspectives
Date:
Wednesday, January 25, 2023 - 8:00 am to Friday, January 27, 2023 - 4:00 pm
Location:
University of California Washington Center (UCDC), 1st floor meeting room
1608 Rhode Island Ave NW, Washington DC
This is Session 1 of 6. Must register for the entire course and not per session.
Session Co-chairpersons:
Charlie T. Gombar, PhD, ACDRS Director
Daniela Drago, PhD RAC FRAPS FTOPRA, Expert Consultant, NDA Partners
Lecturers
Daniela Drago, PhD RAC FRAPS FTOPRA | Expert Consultant, NDA Partners |
Michael Dyszel | Vice President, Product Development Leader, Pyxis Oncology |
Christine Garnett, PharmD | Lead, Interdisciplinary Team for Cardiac Safety Studies and Clinical Analyst, Division of Cardiovascular and Renal Products, Center for Drugs and Evaluation Research (CDER), US Food and Drug Administration (FDA) |
Charlie T. Gombar, PhD | ACDRS Director |
Dionna Green, MD FCP | Director, Office of Pediatric Therapeutics, Office of Clinical Policy and Programs, Office of the Commissioner, US FDA |
Kenneth Kaitin, PhD |
Professor and Senior Fellow, Tufts Center for the Study of Drug Development, Tufts University |
David Macarios, MBA | Vice President, Global Health Economics and Outcomes Research and RWE, Becton Dickinson |
Bernard Munos |
Senior Fellow, FasterCures |
Sally Okun, RN MMHS | Executive Director, Clinical Trials Transformation Initiative, Duke University |
Fortunato (Fred) Senatore, MD PhD FACC | Medical Officer, Division of Cardiovascular and Renal Products, CDER, US FDA |
Mirat Shah, MD | Medical Oncologist and Clinical Reviewer, Office of Oncologic Diseases, CDER, US FDA |
Mary T. Thanh Hai, MD | Deputy Director, Clinical, Office of New Drugs, CDER, US FDA (virtual) (to be confirmed) |
Theo Vos, MD PhD | Professor of Global Health, Institute for Health Metrics and Evaluation, University of Washington |
Additional faculty - case study proctors
Gideon Blumenthal, MD | Vice President Oncology Global Regulatory Affairs, Merck |
Maria Jison, MD | Executive Director Clinical Development/Global Clinical Head - Fasenra, Astrazeneca |
Kofi Mensah, MD PhD | Director, Early Development, Bristol Myers Squibb |
Ki Milligan, MD | Director, Pediatric Center of Excellence, Global Drug Development, Novartis |
Jorge Safi, MD PhD | Senior Global Program Safety Lead, Novartis |
Topics
- History of the pharmaceutical enterprise
- Development timelines
- Principles of contemporary drug development and regulatory science
- Patient perspectives in medical product development
- Pharmacoeconomics, health technology assessment, and methods for comparison of economic value for different products
- Global health trends, disease management, and their effect on health outcomes
- Regulatory pathways for drugs and biologics
- Regulatory landscape and development challenges in pediatric, cell and gene therapies, and novel treatment modalities
- Decision points in development of small and large molecules
- Management science: Portfolio, projects, and teams
- Target product profile: A key strategic tool in product development
- Special topics based on cutting edge science, changing regulations, controversies, etc.